Alirocumab
Top View
- Treatment Strategy for Dyslipidemia in Cardiovascular Disease Prevention: Focus on Old and New Drugs
- PCSK9 Inhibitors
- Alirocumab in Combination with Statins for CVD Risk Reduction: an Evidential Review
- Alirocumab (Praluent®)
- A Review of the Efficacy and Tolerability of Bempedoic Acid In
- Bococizumab for Primary Hyperlipidaemia and Mixed Dyslipidaemia – Adjunctive to Statin Therapy And/Or Diet
- Alirocumab (Praluent) Reference Number: ERX.SPA.168 Effective Date: 01.11.17 Last Review Date: 08.18 Revision Log
- PRALUENT® (Alirocumab) Injection, for Subcutaneous Use LDL Apheresis
- Lipotropics, Other
- CLINICAL REVIEW(S) Clinical Review Ovidiu A
- Alirocumab) Injection, for Subcutaneous Use Initial U.S
- Praluent, INN-Alirocumab
- Introduction Bile Acid Sequestrants
- Genetics of Dyslipidemia
- Praluent, INN-Alirocumab
- The Importance of Lipoprotein Lipase Regulationin Atherosclerosis
- For Review at September 24, 2020, Meeting: Antihyperlipidemics
- Anatomical Classification Guidelines V2018 EPHMRA ANATOMICAL